Licitaciones · 2020014604
suministro de diversos medicamentos exclusivos con destino a los centros sanitarios dependientes de la Gerencia Regional de Salud de Castilla y León
Adjudicada
- Órgano de contratación
- Gerencia Regional de Salud de Castilla y León
- Expediente
- 2020014604
- Presupuesto (sin IVA)
- 138.282.945 €
- Valor estimado
- 439.739.764 €
- Lugar de ejecución
- Valladolid (ES418)
- CPV
- 33652100, 33690000, 33621200, 33621100, 33652300, 33610000, 33651100, 33652200
- Plazo de presentación
- 15 jul 2024
- Última actualización
- 14 jul 2026
Lotes (55)
| Lote | Objeto | Presupuesto (sin IVA) |
|---|---|---|
| 1 | Risankizumab
 
 | 2.285.487 € |
| 10 | Niraparib | 2.220.560 € |
| 11 | belimumab | 1.104.710 € |
| 12 | Abemaciclib | 2.223.656 € |
| 13 | ramucirumab | 1.788.377 € |
| 14 | galcanezumab | 673.400 € |
| 15 | riociguat | 1.474.824 € |
| 16 | raltegravir | 915.727 € |
| 17 | cetuximab | 2.888.445 € |
| 18 | avelumab | 1.391.156 € |
| 19 | eltrombopag | 3.704.678 € |
| 2 | Levodopa e inhibidor de la decarboxilasa | 2.223.271 € |
| 20 | nilotinib | 2.308.680 € |
| 21 | Dabrafenib | 1.318.956 € |
| 22 | Ribociclib | 3.744.934 € |
| 23 | Ruxolitinib | 3.896.369 € |
| 24 | Alpelisib | 987.438 € |
| 25 | Canakinumab | 1.053.113 € |
| 26 | Isavuconazol | 1.519.707 € |
| 27 | Obinutuzumab | 1.041.694 € |
| 28 | Pertuzumab | 5.715.094 € |
| 29 | Laronidase | 931.856 € |
| 3 | Dexametasona oftálmica | 7.257.983 € |
| 30 | Eliglustat | 1.158.830 € |
| 31 | Isatuximab | 904.447 € |
| 32 | Certolizumab | 1.631.626 € |
| 33 | Abatacept | 3.029.672 € |
| 34 | Clevidipino | 911.588 € |
| 35 | Amfotericina B liposomal | 1.647.397 € |
| 36 | Emtricitabina, tenofovir alafenamida y bictegravir | 6.593.920 € |
| 37 | Sacituzumab govitecan | 1.197.912 € |
| 38 | Darolutamida | 758.922 € |
| 39 | Dolutegravir | 1.761.181 € |
| 4 | Romiplostim | 2.022.584 € |
| 40 | Dolutegravir y Rilpivirina | 1.895.227 € |
| 41 | Lamivudina Y Dolutegravir | 5.183.566 € |
| 42 | Selexipag | 2.002.088 € |
| 43 | Macitentan | 2.049.608 € |
| 44 | Darunavir y Cobicistat | 706.957 € |
| 45 | Ibrutinib | 11.160.974 € |
| 46 | Apalutamida | 4.322.757 € |
| 47 | Guselkumab | 3.772.461 € |
| 48 | Agalsidasa Alfa | 1.054.274 € |
| 49 | Idursulfasa | 3.026.054 € |
| 5 | Etelcalcetida | 949.331 € |
| 50 | Vedolizumab | 5.711.506 € |
| 51 | Nintedanib | 283.428 € |
| 52 | Lenvatinib | 991.635 € |
| 53 | Enzalutamida | 6.113.193 € |
| 54 | Patisiran | 772.910 € |
| 55 | Trifluridina | 1.520.900 € |
| 6 | Panitumumab | 2.644.042 € |
| 7 | Carfilzomib | 1.466.559 € |
| 8 | Osimertinib | 6.628.685 € |
| 9 | Acalabrutinib | 1.738.597 € |
Adjudicaciones
| Lote | Adjudicatario | Importe (sin IVA) | Ofertas | Fecha |
|---|---|---|---|---|
| 37 | GILEAD SCIENCES,SL | 1.197.912 € | 1 | — |
| 38 | BAYER HISPANIA, SL | 659.932 € | 1 | 19 sept 2024 |
| 39 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 4 | AMGEN, SA | 2.022.584 € | 1 | 19 sept 2024 |
| 1 | ABBVIE SPAIN, SLU | 2.285.481 € | 1 | 19 sept 2024 |
| 10 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 11 | GLAXOSMITHKLINE, S.A | 1.104.710 € | 1 | 19 sept 2024 |
| 12 | LILLY, S.A. | 2.112.471 € | 1 | 19 sept 2024 |
| 13 | LILLY, S.A. | 1.788.377 € | 1 | 19 sept 2024 |
| 14 | ORGANON SALUD SL. | 622.280 € | 1 | 19 sept 2024 |
| 15 | MERCK SHARP & DOHME DE ESPAÑA, SA | 1.474.824 € | 1 | 19 sept 2024 |
| 16 | MERCK SHARP & DOHME DE ESPAÑA, SA | 915.722 € | 1 | 19 sept 2024 |
| 17 | MERCK, S.L.U. | 2.888.445 € | 1 | 19 sept 2024 |
| 18 | MERCK, S.L.U. | 1.391.156 € | 1 | 19 sept 2024 |
| 19 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 2 | ABBVIE SPAIN, SLU | 2.223.271 € | 1 | 19 sept 2024 |
| 20 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 21 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 22 | NOVARTIS FARMACÉUTICA, SA | 3.744.922 € | 1 | 19 sept 2024 |
| 23 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 24 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 25 | NOVARTIS FARMACÉUTICA, SA | 1.053.113 € | 1 | 19 sept 2024 |
| 26 | PFIZER SL | 1.519.700 € | 1 | 19 sept 2024 |
| 27 | ROCHE FARMA, SA | 1.041.694 € | 1 | 19 sept 2024 |
| 28 | ROCHE FARMA, SA | 5.715.094 € | 1 | 19 sept 2024 |
| 29 | SANOFI-AVENTIS, SA | 931.856 € | 1 | 19 sept 2024 |
| 3 | ABBVIE SPAIN, SLU | 7.257.983 € | 1 | 19 sept 2024 |
| 30 | Sin adjudicatario | — | 0 | 19 sept 2024 |
| 31 | Sin adjudicatario | — | 0 | 19 sept 2024 |
| 32 | UCB PHARMA,SA | 1.569.712 € | 1 | 19 sept 2024 |
| 33 | BRISTOL-MYERS SQUIBB, SAU | 3.029.664 € | 1 | 19 sept 2024 |
| 34 | FERRER FARMA, S.A. | 911.588 € | 1 | 19 sept 2024 |
| 35 | GILEAD SCIENCES,SL | 1.647.397 € | 1 | — |
| 36 | GILEAD SCIENCES,SL | 6.593.920 € | 1 | 19 sept 2024 |
| 40 | LABORATORIOS VIIV HEALTHCARE, SL | 1.895.227 € | 1 | 19 sept 2024 |
| 41 | LABORATORIOS VIIV HEALTHCARE, SL | 5.183.566 € | 1 | 19 sept 2024 |
| 42 | JANSSEN-CILAG, SA | 2.002.088 € | 1 | 19 sept 2024 |
| 43 | Sin adjudicatario | — | 0 | 19 sept 2024 |
| 44 | JANSSEN-CILAG, SA | 706.957 € | 1 | 19 sept 2024 |
| 45 | JANSSEN-CILAG, SA | 10.602.927 € | 1 | 19 sept 2024 |
| 46 | JANSSEN-CILAG, SA | 4.134.811 € | 1 | 19 sept 2024 |
| 47 | JANSSEN-CILAG, SA | 3.772.461 € | 1 | 19 sept 2024 |
| 48 | TAKEDA FARMACÉUTICA ESPAÑA, SA | 975.200 € | 1 | 19 sept 2024 |
| 49 | TAKEDA FARMACÉUTICA ESPAÑA, SA | 3.026.042 € | 1 | 19 sept 2024 |
| 5 | AMGEN, SA | 949.331 € | 1 | 19 sept 2024 |
| 50 | TAKEDA FARMACÉUTICA ESPAÑA, SA | 5.711.491 € | 1 | 19 sept 2024 |
| 51 | BOEHRINGER INGELHEIM ESPAÑA, SA | 283.428 € | 1 | 19 sept 2024 |
| 52 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 53 | ASTELLAS PHARMA, SA | 5.847.402 € | 1 | 19 sept 2024 |
| 54 | ALNYLAM PHARMACEUTICALS SPAIN, S.L | 772.910 € | 1 | 19 sept 2024 |
| 55 | Sin adjudicatario | — | 1 | 19 sept 2024 |
| 6 | AMGEN, SA | 2.644.042 € | 1 | 19 sept 2024 |
| 7 | AMGEN, SA | 1.466.559 € | 1 | 19 sept 2024 |
| 8 | ASTRAZENECA FARMACEUTICA SPAIN, S.A | 6.628.685 € | 1 | 19 sept 2024 |
| 9 | ASTRAZENECA FARMACEUTICA SPAIN, S.A | 1.651.667 € | 1 | 19 sept 2024 |
Ver en la Plataforma de Contratación del Sector Público ↗
Analizar pliego (beta)
Extrae requisitos de solvencia, criterios de adjudicación, garantías y riesgos del PCAP, con un score de accesibilidad para pymes. Tarda ~1 minuto.